Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies.

The unprecedented advances in molecular biology during the last two decades have resulted in a dramatic increase in knowledge about gene structure and function, an immense database of genetic sequence information, and an impressive set of efficient new technologies for monitoring genetic sequences, genetic variation, and global functional gene expression. These advances have led to a new sub-discipline of toxicology: "toxicogenomics". We define toxicogenomics as "the study of the relationship between the structure and activity of the genome (the cellular complement of genes) and the adverse biological effects of exogenous agents". This broad definition encompasses most of the variations in the current usage of this term, and in its broadest sense includes studies of the cellular products controlled by the genome (messenger RNAs, proteins, metabolites, etc.). The new "global" methods of measuring families of cellular molecules, such as RNA, proteins, and intermediary metabolites have been termed "-omic" technologies, based on their ability to characterize all, or most, members of a family of molecules in a single analysis. With these new tools, we can now obtain complete assessments of the functional activity of biochemical pathways, and of the structural genetic (sequence) differences among individuals and species, that were previously unattainable. These powerful new methods of high-throughput and multi-endpoint analysis include gene expression arrays that will soon permit the simultaneous measurement of the expression of all human genes on a single "chip". Likewise, there are powerful new methods for protein analysis (proteomics: the study of the complement of proteins in the cell) and for analysis of cellular small molecules (metabonomics: the study of the cellular metabolites formed and degraded under genetic control). This will likely be extended in the near future to other important classes of biomolecules such as lipids, carbohydrates, etc. These assays provide a general capability for global assessment of many classes of cellular molecules, providing new approaches to assessing functional cellular alterations. These new methods have already facilitated significant advances in our understanding of the molecular responses to cell and tissue damage, and of perturbations in functional cellular systems. As a result of this rapidly changing scientific environment, regulatory and industrial toxicology practice is poised to undergo dramatic change during the next decade. These advances present exciting opportunities for improved methods of identifying and evaluating potential human and environmental toxicants, and of monitoring the effects of exposures to these toxicants. These advances also present distinct challenges. For example, the significance of specific changes and the performance characteristics of new methods must be fully understood to avoid misinterpretation of data that could lead to inappropriate conclusions about the toxicity of a chemical or a mechanism of action. We discuss the likely impact of these advances on the fields of general and genetic toxicology, and risk assessment. We anticipate that these new technologies will (1) lead to new families of biomarkers that permit characterization and efficient monitoring of cellular perturbations, (2) provide an increased understanding of the influence of genetic variation on toxicological outcomes, and (3) allow definition of environmental causes of genetic alterations and their relationship to human disease. The broad application of these new approaches will likely erase the current distinctions among the fields of toxicology, pathology, genetic toxicology, and molecular genetics. Instead, a new integrated approach will likely emerge that involves a comprehensive understanding of genetic control of cellular functions, and of cellular responses to alterations in normal molecular structure and function.

[1]  E Holmes,et al.  Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks. , 2001, Chemical research in toxicology.

[2]  J. T. Macgregor,et al.  Strategies and testing methods for identifying mutagenic risks. , 2000, Mutation research.

[3]  J. Degeorge Challenges in application of new approaches to carcinogenicity testing for pharmaceuticals. , 1998, Toxicology Letters.

[4]  W. Kalow Contribution of hereditary factors to the response to drugs. , 1965, Federation proceedings.

[5]  J R Yates,et al.  Mass spectrometry. From genomics to proteomics. , 2000, Trends in genetics : TIG.

[6]  T. Lindahl,et al.  Quality control by DNA repair. , 1999, Science.

[7]  G. H. Bush,et al.  Pharmacogenetics , 1968 .

[8]  E. Sim,et al.  Arylamine N-acetyltransferases - of mice, men and microorganisms. , 2001, Trends in pharmacological sciences.

[9]  P. de Knijff,et al.  A powerful and rapid approach to human genome scanning using small quantities of genomic DNA. , 2001, Genetical research.

[10]  S. Cohen,et al.  The manipulation of genes. , 1975, Scientific American.

[11]  S. Schreiber,et al.  Printing proteins as microarrays for high-throughput function determination. , 2000, Science.

[12]  W. Kalow I. Drug metabolism enzymes. Pharmacogenetics in animals and man. , 1968, Annals of the New York Academy of Sciences.

[13]  S. Gottesman,et al.  Posttranslational quality control: folding, refolding, and degrading proteins. , 1999, Science.

[14]  D. Mccormick Sequence the Human Genome , 1986, Bio/Technology.

[15]  R. Dunn,et al.  Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  I F Purchase,et al.  Transgenic animals in toxicology. , 1994, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[17]  A. J. Lehman,et al.  Procedures for the appraisal of the toxicity of chemicals in foods. , 1949, Food, Drug, cosmetic law quarterly.

[18]  F. Taddei,et al.  Counteraction by MutT protein of transcriptional errors caused by oxidative damage. , 1997, Science.

[19]  A. Ronen,et al.  Human DNA repair genes , 2001, Environmental and molecular mutagenesis.

[20]  F. A. Denz,et al.  Experimental methods used in determining chronic toxicity; a critical review. , 1954, Pharmacological reviews.

[21]  L. Samson,et al.  Global response of Saccharomyces cerevisiae to an alkylating agent. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Toward construction of a transcript profile database predictive of chemical toxicity. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  Jørgen K. Kanters,et al.  Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MiRP1 ion channel: implications for acquired and congenital long Q-T syndrome. , 2001, Clinical chemistry.

[24]  W. Weber,et al.  Populations and genetic polymorphisms. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[25]  F. Crick,et al.  Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid , 1974, Nature.

[26]  N. Anderson,et al.  Simultaneous Measurement of Hundreds of Liver Proteins: Application in Assessment of Liver Function , 1996, Toxicologic pathology.

[27]  J. Lederberg,et al.  `Ome Sweet `Omics--A Genealogical Treasury of Words , 2001 .

[28]  F. Kadlubar Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. , 1994, Drug metabolism reviews.

[29]  Steven J Smith,et al.  Cardiovascular Toxicity of Antihistamines , 1994, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[30]  B. W. Penman,et al.  Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. , 1997, Advances in pharmacology.

[31]  D J Dix,et al.  Application of DNA arrays to toxicology. , 1999, Environmental health perspectives.

[32]  M Pirmohamed,et al.  Genetic susceptibility to adverse drug reactions. , 2001, Trends in pharmacological sciences.

[33]  R. Langenbach,et al.  Human cell lines, derived from AHH-1 TK+/- human lymphoblasts, genetically engineered for expression of cytochromes P450. , 1993, Toxicology.

[34]  F. Kadlubar,et al.  Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. , 1995, Pharmacogenetics.

[35]  R. Dunn,et al.  Concise review: gene expression applied to toxicology. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  T. Ørntoft,et al.  Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics , 2000, FEBS letters.

[37]  W. Pennie Use of cDNA microarrays to probe and understand the toxicological consequences of altered gene expression. , 2000, Toxicology letters.

[38]  T. Nyström,et al.  Protein oxidation in response to increased transcriptional or translational errors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Egan,et al.  Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. , 1996, Arzneimittel-Forschung.

[40]  L J Lesko,et al.  Pharmacogenomic-guided drug development: regulatory perspective , 2002, The Pharmacogenomics Journal.

[41]  J. Yates,et al.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.

[42]  J. Trent,et al.  Microarrays and toxicology: The advent of toxicogenomics , 1999, Molecular carcinogenesis.

[43]  J. Speyer,et al.  Synthetic polynucleotides and the amino acid code. , 1961, Proceedings of the National Academy of Sciences of the United States of America.

[44]  George M. Church,et al.  Regulatory Networks Revealed by Transcriptional Profiling of Damaged Saccharomyces cerevisiae Cells: Rpn4 Links Base Excision Repair with Proteasomes , 2000, Molecular and Cellular Biology.

[45]  W. Weber Effect of pharmacogenetics on medicine , 2001, Environmental and molecular mutagenesis.

[46]  D. Nebert Drug-Metabolizing Enzymes, Polymorphisms and Interindividual Response to Environmental Toxicants , 2000, Clinical chemistry and laboratory medicine.

[47]  E Holmes,et al.  Chemometric models for toxicity classification based on NMR spectra of biofluids. , 2000, Chemical research in toxicology.

[48]  J. Yates Mass spectrometry and the age of the proteome. , 1998, Journal of mass spectrometry : JMS.

[49]  A Helenius,et al.  Setting the standards: quality control in the secretory pathway. , 1999, Science.

[50]  R G Ulrich,et al.  Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. , 2001, Toxicology letters.

[51]  Katsushi Tokunaga,et al.  The power of genome-wide association studies of complex disease genes: statistical limitations of indirect approaches using SNP markers , 2001, Journal of Human Genetics.

[52]  J. Lindon,et al.  'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.